Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0533
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism ; day:8 ; month:12 ; year:2016 ; pages:1-12
Acta neuropathologica ; (8.12.2016), 1-12
- Contributor
-
Chapuis, Julien
Flaig, Amandine
Grenier-Boley, Benjamin
Eysert, Fanny
Pottiez, Virginie
Deloison, Gaspard
Vandeputte, Alexandre
Ayral, Anne-Marie
Mendes, Tiago
Desai, Shruti
Goate, Alison M.
Kauwe, John S. K.
Leroux, Florence
Herledan, Adrien
Demiautte, Florie
Bauer, Charlotte
Checler, Frederic
Petersen, Ronald C.
Blennow, Kaj
Zetterberg, Henrik
Minthon, Lennart
Deerlin, Vivianna M. Van
Lee, Virginia Man-Yee
Shaw, Leslie M.
Trojanowski, John Q.
Albert, Marilyn
Moghekar, Abhay
O’Brien, Richard
Peskind, Elaine R.
Malmanche, Nicolas
Schellenberg, Gerard D.
Dourlen, Pierre
Song, Ok-Ryul
Cruchaga, Carlos
Amouyel, Philippe
Déprez, Benoit
Brodin, Priscille
Lambert, Jean-Charles
SpringerLink (Online service)
- DOI
-
10.1007/s00401-016-1652-z
- URN
-
urn:nbn:de:1111-201701055951
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chapuis, Julien
- Flaig, Amandine
- Grenier-Boley, Benjamin
- Eysert, Fanny
- Pottiez, Virginie
- Deloison, Gaspard
- Vandeputte, Alexandre
- Ayral, Anne-Marie
- Mendes, Tiago
- Desai, Shruti
- Goate, Alison M.
- Kauwe, John S. K.
- Leroux, Florence
- Herledan, Adrien
- Demiautte, Florie
- Bauer, Charlotte
- Checler, Frederic
- Petersen, Ronald C.
- Blennow, Kaj
- Zetterberg, Henrik
- Minthon, Lennart
- Deerlin, Vivianna M. Van
- Lee, Virginia Man-Yee
- Shaw, Leslie M.
- Trojanowski, John Q.
- Albert, Marilyn
- Moghekar, Abhay
- O’Brien, Richard
- Peskind, Elaine R.
- Malmanche, Nicolas
- Schellenberg, Gerard D.
- Dourlen, Pierre
- Song, Ok-Ryul
- Cruchaga, Carlos
- Amouyel, Philippe
- Déprez, Benoit
- Brodin, Priscille
- Lambert, Jean-Charles
- SpringerLink (Online service)
Other Objects (12)
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
CSF Presenilin-1 complexes are increased in Alzheimer’s disease